Streetbeat News

Regulatory

ABTC

BTCUSD

BTCW

CBTC

The first Bitcoin exchange-traded products (ETPs) have started trading on the London Stock Exchange, marking a significant milestone for cryptocurrency adoption in the U.K. Asset managers WisdomTree and 21Shares listed Bitcoin ETPs, including 21Shares Bitcoin ETN (ABTC), 21Shares Bitcoin Core ETN (CBTC), and WisdomTree Physical Bitcoin ETN (BTCW). These products are currently accessible only to professional investors under FCA regulations.

Portfolio Pulse from Benzinga Neuro

May 28, 2024 | 12:51 pm

APRE

Aprea Therapeutics' Safety Review Committee has endorsed dosing patients with ATRN-119 in the ABOYA-119 clinical trial. ATRN-119, a macrocyclic ATR inhibitor, has shown safety and tolerance through the first 5 cohorts with no dose-limiting toxicities. The company is on track to complete dose escalation and potentially generate initial human efficacy data in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 12:48 pm

PTCT

PTC Therapeutics announced that the European Medicines Agency (EMA) has validated and accepted the marketing authorization application (MAA) for sepiapterin, a treatment for phenylketonuria (PKU).

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 12:45 pm

CATC

EBC

Eastern Bankshares, Inc. (EBC) and Cambridge Bancorp (CATC) have received all necessary regulatory approvals for their proposed merger, expected to close on or about July 12, 2024.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 12:44 pm

CRMD

CorMedix Inc. (NASDAQ:CRMD) has entered into a multi-year commercial supply contract with a top tier midsized dialysis provider for its product DefenCath. The company received NDA approval for DefenCath on November 15, 2023, and began commercialization in the inpatient setting on April 15th. Outpatient commercialization is expected to start in July, expanding access to over 500 dialysis facilities nationwide.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 12:43 pm

BNIX

Bannix Acquisition Corp. has received a non-compliance notification from NASDAQ, indicating that the company is not meeting the exchange's listing requirements.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 12:37 pm

NIVF

NewGenIvf has received two letters from Nasdaq. The first letter is a notification of non-compliance with Nasdaq's minimum bid price requirement, as the company's stock has closed below $1.00 per share for 30 consecutive business days. The second letter is a notification of non-compliance with Nasdaq's minimum stockholders' equity requirement, as the company's stockholders' equity is below $2.5 million. NewGenIvf has 180 calendar days to regain compliance with the minimum bid price requirement and 45 calendar days to submit a plan to regain compliance with the minimum stockholders' equity requirement.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 12:34 pm

AMRN

Amarin Corporation announced that the Greek Ministry of Health has approved national reimbursement for VAZKEPA, a drug aimed at reducing cardiovascular events in high-risk statin-treated adults.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 12:17 pm

OTLK

Outlook Therapeutics has received marketing authorization from the European Commission for its drug LYTENAVA, which is used to treat retina diseases.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 12:10 pm

HUGE

FSD Pharma has submitted a clinical trial protocol to assess the safety and efficacy of Unbuzzd, a product aimed at mitigating the effects of alcohol consumption. This development could have significant implications for the company's future growth and product portfolio.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 12:08 pm